id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-267564-ulavigi7	Remington, K. M.	Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products	2004-07-16		.txt	text/plain	5099	285	49	Conclusions This study demonstrates that procedures used to inactivate enveloped viruses in manufacturing processes can achieve inactivation of West Nile virus and vaccinia virus. However, recent outbreaks of emergent viruses, such as West Nile virus ( WNV ), severe acute respiratory syndrome (SARS)-associated coronavirus and monkeypox, have indicated that potential threats to the blood supply exist and have resulted in a re-evaluation of the current pathogen safety strategy for plasma products. For VV-, WNV-or BVDV-inactivation studies, concentrated TNBP/ cholate from a stock solution was added to an aliquot of process intermediate to 0·3%/0·2% or to 0·15%/0·1% and then spiked to 10% (v/v) with virus. Table 3 Virus inactivation by tri-(n-butyl)-phosphate (TNBP)/Tween 80 in solutions of anti-haemophilic factor (AHF) or TNBP/cholate in intravenous immunoglobulin produced using the solvent/detergent process (IVIG-S/D) Incubation of WNV in an IVIG-S/D process intermediate solution, containing either 0·3% TNBP/0·2% cholate (manufacturing conditions) or 0·15% TNBP/0·1% cholate, resulted in complete inactivation of the virus within 30 min (Fig. 1c) .	./cache/cord-267564-ulavigi7.txt	./txt/cord-267564-ulavigi7.txt